Developer docs
API playgroundTry for free, no card

Search company profiles

PainChek

Full company profile

uuid0003zz3

Namestring
PainChek
Legal namestring
PainChek Limited
Websiteurl
painchek.com
Company typeenum
Public
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pain assessment software, AI healthcare technology, aged care software, clinical decision support, medical device software
Industry2 codes
1SaMD – Digital Biomarkers & Algorithmic Endpoints
CodeHLACANAFPrimaryYes
2SaMD – Imaging & Signal Analysis (AI/ML)
CodeHLACANAGPrimaryNo
SIC code1 code
  • Services-Health Services8000
Product category
Clinical pain assessment software
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Per-Bed License Fees
TypeSubscription Recurring
Description

Annual recurring license fees charged per bed in aged care facilities. In the US market, pricing is set at $55-75 USD per bed per annum under perpetual agreement with Sabra Health Care REIT.

tradingview.com
2UK License Revenue
TypeSubscription Recurring
Description

Contracted licenses in UK aged care market generating approximately A$230,000 in annual recurring revenue from 4,000 new contracted licenses (9% quarterly growth).

tipranks.com
3RTM Reimbursement
TypeSubscription Recurring
Description

Remote Therapeutic Monitoring reimbursement claims through US Centers for Medicare & Medicaid Services. Enables recurring revenue streams for technology-enabled pain assessment services.

painchek.com
4Professional Services
TypeProfessional Services
Description

Training services, implementation support, and remote clinical onboarding provided as part of license agreements. Includes digital training via video conferencing and eLearning platform access.

painchek.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details3 tiers
1US Per-Bed Annual License
ModelSubscriptionBilling cadenceAnnual
Notes

US$55-75 per bed per annum under perpetual master services agreement. Deal with Sabra Health Care REIT covers up to 20,000 beds.

tradingview.com
2UK License Contracts
ModelSubscriptionBilling cadenceAnnual
Notes

UK market generating approximately A$230,000 annual recurring revenue from 4,000 contracted licenses. 9% quarterly growth in contracted licenses.

tipranks.com
3Enterprise Multi-Facility
ModelSubscriptionBilling cadenceAnnual
Notes

Large provider contracts including Catholic Healthcare implementing across all residential and home care services. Enterprise pricing negotiated per contract.

painchek.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

PainChek develops and licenses AI-powered pain assessment software that uses smartphone-based facial recognition to detect pain in individuals who cannot reliably self-report, combined with five additional clinical assessment domains covering 42 indicators. The platform is delivered as a mobile app (PainChek Universal and PainChek Infant), a cloud analytics portal, and APIs that integrate with leading care management and medication management systems for residential aged care, home care, disability, hospital, and infant care providers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 14 values shown
  • 42% reduction in falls in Scottish pilot
+13 more records
Product overview1 text field

PainChek Universal is a unified AI-powered pain assessment platform combining a mobile application, analytics portal, and API data access. The core PainChek Universal platform uses AI facial recognition to assess pain in individuals who cannot reliably self-report (including those with dementia, cognitive impairments, or infants), while also including the Numeric Rating Scale for those who can communicate their pain. PainChek Analytics provides built-in data intelligence for clinical decision-making. The portfolio serves aged care, home care, disability, hospitals, and infant care sectors, integrating with leading care management and medication management systems across Australia, New Zealand, UK, Canada, and the US. The company holds 20+ million clinical assessments, FDA De Novo clearance (DEN240073), and operates across 1,900+ facilities globally.

Product and service3 records
1PainChek Universal
CategoryPain assessment software platform
Description

AI-powered pain assessment platform for residential aged care, home care, disability, and hospital providers. Uses smartphone facial recognition to detect pain in individuals who cannot reliably self-report (including those with moderate to severe dementia) and includes a Numeric Rating Scale for self-reporting patients. Available on iOS and Android with cloud analytics.

2PainChek Infant
CategoryInfant pain assessment app
Description

AI-powered smartphone app for identifying likelihood of pain in infants aged 1-12 months. Helps parents and caregivers identify pain in babies who cannot communicate distress, tracks pain reliably, and supports informed care decisions. Available on iOS and Android.

3PainChek Analytics
CategoryClinical analytics portal
Description

Cloud-based data intelligence portal that consolidates historical pain assessment data and provides real-time insights, trend analysis, monthly management dashboards, and predictive analytics for optimising pain management and clinical outcomes. Available to PainChek licensees at no extra cost.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-14
Description

Landmark master services agreement to deploy PainChek's AI-powered pain assessment technology across up to 20,000 beds in 329 facilities across the US and Canada. Sabra is a Nasdaq-listed REIT with US$5 billion market cap. Pricing at US$55-75 per bed annually. First major entry into North American market.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-07
Description

Strategic partnership with MED e-care's electronic medication management (eMAR) system to promote best practice pain management and address polypharmacy in UK care homes. Combines AI-driven pain assessment with medication monitoring.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-05-20
Description

Partnership to expand US market by integrating PainChek with Eldermark's care management and EHR solutions for senior living facilities. Enables seamless adoption into US long-term care workflows.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-11-17
Description

Partnership with BESTMED for medication management integration. Workflow improvements underway with medication management partners in Australia and NZ.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-03-24
Description

Two-way integration with Nourish Care's app-based care planning platform, accredited by PRSB as Quality Partner. Enables pain assessment scores and observations to surface at point of care, supporting better decision-making and eliminating duplication.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-03-23
Description

Integration with MPS Connect's MediSphere medication management system for complete pain assessment and treatment in one software system. Supports aged care and home care markets.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-10-22
Description

Six-month trial of PainChek in NDIS participants across five shared residential homes. First disability services partnership to validate pain detection in individuals with complex disabilities and behavioural challenges.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-10-07
Description

Research partnership with Ramsay Health Care and Edith Cowan University to investigate ways of minimizing or stopping progression of frailty in hospital patients through better pain management using PainChek.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-10-07
Description

Research partnership with Ramsay Hospital Research Foundation to lead consortium of 12 researchers investigating nurse-led volunteer support and optimal pain management through PainChek for frail hospital patients.

Strategic tierCoreTypeTechnology or Integration
Description

Integration partnership enabling PainChek assessments to be surfaced within PointClickCare's care management platform. Key US market integration covering large segment of senior living facilities.

Strategic tierCoreTypeTechnology or Integration
Description

Integration partnership to bring PainChek into Yardi's senior living technology workflows in the US market.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership with CPR Kids, a Certified Social Enterprise, for PainChek Infant app. Includes clinical review, co-development of parent and clinician education materials, and professional engagement activities.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership for North American headquarters opening in Edmonton, Alberta. Supported by Edmonton Global economic development organization with Mayor and Alberta Health Ministers in attendance.

Strategic tierCoreTypeTechnology or Integration
Description

Integration partnership with UK's largest digital care management platform. PainChek assessments automatically sent to care management system. When PainChek identifies pain, automatic 'must do' reassessment alert generated.

Strategic tierCoreTypeTechnology or Integration
Description

Integration with AlayaCare's cloud-based home care software platform for Canadian market. Covers significant portion of aged care beds in Australia and supports international expansion.

Strategic tierCoreTypeTechnology or Integration
Description

Integration partnership with Ascom for UK market. New integration launched supporting pain data visibility in clinical workflows.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Huma provides regulated remote patient monitoring and digital-health infrastructure for care organizations. It is comparable to PainChek through its regulated clinical data platform and provider workflow, although it addresses a broader set of conditions and biomarkers.

TypeBroad incumbent
Description

PointClickCare is a major care-management and electronic-record platform for senior care providers. It is comparable through its aged-care customer base and workflow position, while also serving as a channel through which PainChek assessments can be surfaced.

TypeEmerging player
Description

SafelyYou provides AI-enabled fall detection and care insights for senior living and dementia care. It serves many of the same care facilities and vulnerable populations as PainChek, but addresses fall management rather than pain identification.

TypeBroad incumbent
Description

AlayaCare is a home-care management and remote-monitoring platform used by aged-care providers. It is comparable because both companies target home-care organizations and embed data into caregiver workflows, and AlayaCare also acts as a PainChek integration partner.

TypeBroad incumbent
Description

Hinge Health is a scaled digital musculoskeletal pain-management platform combining technology-enabled exercise and coaching. It is comparable through its focus on measurable pain improvement, while its employer- and payer-oriented model and self-directed MSK treatment are broader than PainChek's caregiver-led assessment tool.

TypeBroad incumbent
Description

Sword Health provides digital musculoskeletal care using remote clinicians, exercise therapy, and patient engagement technology. It shares PainChek's objective of using digital tools to improve pain management, but targets a narrower treatment pathway and different buyer set.

TypeEmerging player
Description

Binah.ai uses camera-based AI to extract health-related measurements from video. It is technically comparable to PainChek through smartphone video analysis and health-data generation, but its core outputs are vital signs and wellness measurements rather than pain assessment.

TypeEmerging player
Description

NuraLogix develops contactless, camera-based health-measurement technology using signal analysis. Its AI extraction of health information from video is comparable to PainChek's imaging and multimodal analysis, although NuraLogix emphasizes general vital signs and chronic-disease risk.

TypeDirect peer
Description

PainDrainer applies digital and AI-enabled tools to chronic-pain assessment and management. It is comparable to PainChek because both use technology to improve pain decisions, although PainDrainer is more patient-facing and PainChek is focused on professional caregivers and people unable to self-report.

TypeEmerging player
Description

Best Buy Health's Current Health business offers remote patient monitoring through connected devices and a clinical platform. It is comparable through remote monitoring, longitudinal data, and home-based care, but focuses on physiological monitoring rather than facial and behavioral pain assessment.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers16 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration21 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PainChek

Clinical pain assessment softwarepainchek.com

PainChek firmographics

Firmographics
Name
PainChek
Legal name
PainChek Limited
Website
https://painchek.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

PainChek industry classification

Industry
Product category
Clinical pain assessment software
SIC
Services-Health Services (8000)
akta.pro primary industry
SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)
akta.pro secondary industry
SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

Keywords

  • Pain assessment software
  • AI healthcare technology
  • Aged care software
  • Clinical decision support
  • Medical device software

Where PainChek is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Offices4 records

Markets served

PainChek business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Per-Bed License Fees: Annual recurring license fees charged per bed in aged care facilities. In the US market, pricing is set at $55-75 USD per bed per annum under perpetual agreement with Sabra Health Care REIT.
  2. UK License Revenue: Contracted licenses in UK aged care market generating approximately A$230,000 in annual recurring revenue from 4,000 new contracted licenses (9% quarterly growth).
  3. RTM Reimbursement: Remote Therapeutic Monitoring reimbursement claims through US Centers for Medicare & Medicaid Services. Enables recurring revenue streams for technology-enabled pain assessment services.
  4. Professional Services: Training services, implementation support, and remote clinical onboarding provided as part of license agreements. Includes digital training via video conferencing and eLearning platform access.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualUS Per-Bed Annual License
SubscriptionAnnualUK License Contracts
SubscriptionAnnualEnterprise Multi-Facility

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

PainChek product offering

Product offering

Core offering

PainChek develops and licenses AI-powered pain assessment software that uses smartphone-based facial recognition to detect pain in individuals who cannot reliably self-report, combined with five additional clinical assessment domains covering 42 indicators. The platform is delivered as a mobile app (PainChek Universal and PainChek Infant), a cloud analytics portal, and APIs that integrate with leading care management and medication management systems for residential aged care, home care, disability, hospital, and infant care providers.

Product overview

PainChek Universal is a unified AI-powered pain assessment platform combining a mobile application, analytics portal, and API data access. The core PainChek Universal platform uses AI facial recognition to assess pain in individuals who cannot reliably self-report (including those with dementia, cognitive impairments, or infants), while also including the Numeric Rating Scale for those who can communicate their pain. PainChek Analytics provides built-in data intelligence for clinical decision-making. The portfolio serves aged care, home care, disability, hospitals, and infant care sectors, integrating with leading care management and medication management systems across Australia, New Zealand, UK, Canada, and the US. The company holds 20+ million clinical assessments, FDA De Novo clearance (DEN240073), and operates across 1,900+ facilities globally.

Differentiator

Problem solved

Functional benefit

Products and services

  • PainChek Universal AI-powered pain assessment platform for residential aged care, home care, disability, and hospital providers. Uses smartphone facial recognition to detect pain in individuals who cannot reliably self-report (including those with moderate to severe dementia) and includes a Numeric Rating Scale for self-reporting patients. Available on iOS and Android with cloud analytics.
  • PainChek Infant AI-powered smartphone app for identifying likelihood of pain in infants aged 1-12 months. Helps parents and caregivers identify pain in babies who cannot communicate distress, tracks pain reliably, and supports informed care decisions. Available on iOS and Android.
  • PainChek Analytics Cloud-based data intelligence portal that consolidates historical pain assessment data and provides real-time insights, trend analysis, monthly management dashboards, and predictive analytics for optimising pain management and clinical outcomes. Available to PainChek licensees at no extra cost.

Quantifiable outcome

  • 42% reduction in falls in Scottish pilot
  • +13 more outcomes

Companies that use PainChek

Customer profile

Named customers16 records

Segments5 records

Ideal customer profiles4 records

PainChek technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration21 records

AI capability6 records

Feature6 records

PainChek partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered flagship, core and minor.

  • Sabra Health Care REITflagshipStrategic or Co-development Partner · 14 April 2026Landmark master services agreement to deploy PainChek's AI-powered pain assessment technology across up to 20,000 beds in 329 facilities across the US and Canada. Sabra is a Nasdaq-listed REIT with US$5 billion market cap. Pricing at US$55-75 per bed annually. First major entry into North American market.
  • MED e-carecoreTechnology or Integration · 7 November 2025Strategic partnership with MED e-care's electronic medication management (eMAR) system to promote best practice pain management and address polypharmacy in UK care homes. Combines AI-driven pain assessment with medication monitoring.
  • Eldermark SoftwarecoreTechnology or Integration · 20 May 2025Partnership to expand US market by integrating PainChek with Eldermark's care management and EHR solutions for senior living facilities. Enables seamless adoption into US long-term care workflows.
  • BESTMEDcoreTechnology or Integration · 17 November 2024Partnership with BESTMED for medication management integration. Workflow improvements underway with medication management partners in Australia and NZ.
  • Nourish CarecoreTechnology or Integration · 24 March 2022Two-way integration with Nourish Care's app-based care planning platform, accredited by PRSB as Quality Partner. Enables pain assessment scores and observations to surface at point of care, supporting better decision-making and eliminating duplication.
  • MPS ConnectcoreTechnology or Integration · 23 March 2022Integration with MPS Connect's MediSphere medication management system for complete pain assessment and treatment in one software system. Supports aged care and home care markets.
  • Nulsen GroupminorStrategic or Co-development Partner · 22 October 2020Six-month trial of PainChek in NDIS participants across five shared residential homes. First disability services partnership to validate pain detection in individuals with complex disabilities and behavioural challenges.
  • Ramsay Hospital Research FoundationminorStrategic or Co-development Partner · 7 October 2020Research partnership with Ramsay Health Care and Edith Cowan University to investigate ways of minimizing or stopping progression of frailty in hospital patients through better pain management using PainChek.
  • Edith Cowan University (ECU)minorStrategic or Co-development Partner · 7 October 2020Research partnership with Ramsay Hospital Research Foundation to lead consortium of 12 researchers investigating nurse-led volunteer support and optimal pain management through PainChek for frail hospital patients.
  • PointClickCarecoreTechnology or IntegrationIntegration partnership enabling PainChek assessments to be surfaced within PointClickCare's care management platform. Key US market integration covering large segment of senior living facilities.
  • YardicoreTechnology or IntegrationIntegration partnership to bring PainChek into Yardi's senior living technology workflows in the US market.
  • CPR KidsminorStrategic or Co-development PartnerPartnership with CPR Kids, a Certified Social Enterprise, for PainChek Infant app. Includes clinical review, co-development of parent and clinician education materials, and professional engagement activities.
  • Edmonton GlobalminorStrategic or Co-development PartnerPartnership for North American headquarters opening in Edmonton, Alberta. Supported by Edmonton Global economic development organization with Mayor and Alberta Health Ministers in attendance.
  • Person Centred SoftwarecoreTechnology or IntegrationIntegration partnership with UK's largest digital care management platform. PainChek assessments automatically sent to care management system. When PainChek identifies pain, automatic 'must do' reassessment alert generated.
  • AlayaCarecoreTechnology or IntegrationIntegration with AlayaCare's cloud-based home care software platform for Canadian market. Covers significant portion of aged care beds in Australia and supports international expansion.
  • AscomcoreTechnology or IntegrationIntegration partnership with Ascom for UK market. New integration launched supporting pain data visibility in clinical workflows.

Scale indicators13 records

Recent moves8 records

Expansion highlights7 records

PainChek competitors and assessment

Company assessment

Emerging players

  • Huma: Huma provides regulated remote patient monitoring and digital-health infrastructure for care organizations. It is comparable to PainChek through its regulated clinical data platform and provider workflow, although it addresses a broader set of conditions and biomarkers.
  • SafelyYou: SafelyYou provides AI-enabled fall detection and care insights for senior living and dementia care. It serves many of the same care facilities and vulnerable populations as PainChek, but addresses fall management rather than pain identification.
  • Binah.ai: Binah.ai uses camera-based AI to extract health-related measurements from video. It is technically comparable to PainChek through smartphone video analysis and health-data generation, but its core outputs are vital signs and wellness measurements rather than pain assessment.
  • NuraLogix: NuraLogix develops contactless, camera-based health-measurement technology using signal analysis. Its AI extraction of health information from video is comparable to PainChek's imaging and multimodal analysis, although NuraLogix emphasizes general vital signs and chronic-disease risk.
  • Best Buy Health (Current Health): Best Buy Health's Current Health business offers remote patient monitoring through connected devices and a clinical platform. It is comparable through remote monitoring, longitudinal data, and home-based care, but focuses on physiological monitoring rather than facial and behavioral pain assessment.

Broad incumbents

  • PointClickCare: PointClickCare is a major care-management and electronic-record platform for senior care providers. It is comparable through its aged-care customer base and workflow position, while also serving as a channel through which PainChek assessments can be surfaced.
  • AlayaCare: AlayaCare is a home-care management and remote-monitoring platform used by aged-care providers. It is comparable because both companies target home-care organizations and embed data into caregiver workflows, and AlayaCare also acts as a PainChek integration partner.
  • Hinge Health: Hinge Health is a scaled digital musculoskeletal pain-management platform combining technology-enabled exercise and coaching. It is comparable through its focus on measurable pain improvement, while its employer- and payer-oriented model and self-directed MSK treatment are broader than PainChek's caregiver-led assessment tool.
  • Sword Health: Sword Health provides digital musculoskeletal care using remote clinicians, exercise therapy, and patient engagement technology. It shares PainChek's objective of using digital tools to improve pain management, but targets a narrower treatment pathway and different buyer set.

Direct peers

  • PainDrainer: PainDrainer applies digital and AI-enabled tools to chronic-pain assessment and management. It is comparable to PainChek because both use technology to improve pain decisions, although PainDrainer is more patient-facing and PainChek is focused on professional caregivers and people unable to self-report.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

PainChek social profiles

Digital presence

PainChek compliance and trust

Trust signal

Compliance8 records

PainChek financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PainChek leadership team

Management profile

Number of profiles

Profiles14 records

PainChek subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

PainChek funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PainChek M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PainChek

What does PainChek do?

PainChek develops and licenses AI-powered pain assessment software that uses smartphone-based facial recognition to detect pain in individuals who cannot reliably self-report, combined with five additional clinical assessment domains covering 42 indicators. The platform is delivered as a mobile app (PainChek Universal and PainChek Infant), a cloud analytics portal, and APIs that integrate with leading care management and medication management systems for residential aged care, home care, disability, hospital, and infant care providers.

Is PainChek a public or private company?

PainChek is a public company. It is classified as public and is currently operating.

When was PainChek founded?

PainChek was founded in 2016. It employs 11 to 50 people.

Where is PainChek based?

PainChek is headquartered in Sydney, Australia, in the Oceania region.

How does PainChek make money?

Four revenue lines are on record. Per-Bed License Fees are the primary driver. The others are UK License Revenue, RTM Reimbursement and professional Services.

Who are PainChek's main competitors?

Emerging players on record are Huma, SafelyYou, Binah.ai, NuraLogix and Best Buy Health (Current Health). Broad incumbents are PointClickCare, AlayaCare, Hinge Health and Sword Health. PainDrainer is listed as a direct peer.

Does PainChek have an API?

Yes. Clinical leaders can access data via an API, enabling sophisticated analysis at organisational, facility, and individual level for both users and residents. Access is available to clients as part of their PainChek license. No public documentation, SDK, or developer portal specified.

What industry is PainChek in?

PainChek's product category is Clinical pain assessment software. Its primary akta.pro industry code is HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingPainChek hits over four-month high on expanded Sabra agreement uptakePainChek shares rose 41.4% to A$0.140, its highest since June 4, after the medtech firm reported expanded commercial uptake under its master services agreement with Sabra Health Care REIT. The expansion extends its Sabra footprint to 23 US communities across five operators, with nearly 9.7 times the 30-day average volume traded.KalkinePainChek (ASX:PCK) Updates Governance Structure Amid Ongoing Commercial ExpansionPainChek Ltd appointed Lilian Bianchi as a Director effective May 25, 2026, with the appointment disclosed through an Appendix 3X filing that confirmed the new director held no relevant interests in company securities at the time of appointment. The company's shares remained flat at AUD 0.15 following the announcement, with the market interpreting the routine governance disclosure as neutral from a valuation perspective. The article notes that investors are focused on commercial adoption and regulatory progress rather than governance filings for assessing the company's outlook.GrafaASX-listed PainChek secures major US deal with Sabra REITPainChek announced a master services agreement with Sabra Health Care REIT to deploy its AI-powered pain assessment solution across its portfolio in the US and Canada. The deal involves funding the technology for up to 20,000 beds and marks a significant commercial milestone for PainChek following its FDA approval.StockheadHealth Check: PainChek shares surge after AI innovator’s landmark North American dealPainChek has signed a master services agreement with Nasdaq-listed Sabra Inc to deploy its AI-driven pain assessment tool across up to 20,000 aged care beds in North America, with pricing of US$55-75 per bed annually; the deal provides a blueprint for expansion to other large US real estate investment trusts owning senior living facilities. The company's shares surged as much as 46% on the news, though they remain down 40% year-to-date. The article also covers funding rounds and milestones for Blinklab (seeking $15M for FDA autism detection device approval), Lumos Diagnostics (receiving $5M milestone payment for FebriDx US commercialisation), Audeara (reporting its second consecutive quarter of positive cash flow), and Clarity Pharmaceuticals (signing a commercial manufacturing agreement for its prostate cancer imaging agent).ntnewsPainChek shares surge on US dealPainChek has signed a master services agreement with US aged care property trust Sabra Inc to deploy its AI-driven pain assessment app across up to 20,000 beds, representing the Australian company's first major entry into the North American market. Sabra, a Nasdaq-listed REIT with a US$5 billion market cap operating 329 nursing homes across the US and Canada, will pay an annual per-bed fee of US$55-75, with PainChek shares surging as much as 46% on the announcement. The article also notes that Blinklab is seeking A$15 million in a capital raising to fund FDA approval trials for its autism detection device, while Lumos Diagnostics received a US$5 million milestone payment related to its FebriDx bacterial-versus-viral testing device.TradingViewPainChek Inks Landmark 20,000-Bed North America Deployment with Sabra Health Care REITPainChek has signed a Master Services Agreement with Sabra Health Care REIT to deploy its pain assessment technology across up to 20,000 beds in 329 facilities across the US and Canada, with pricing set at $55-75 USD per bed per annum under a perpetual agreement. The agreement follows PainChek's FDA De Novo clearance for its Adult App in October 2025 and eligibility for US Remote Therapeutic Monitoring reimbursement, which enables recurring revenue streams for assessing pain in non-verbal dementia patients. The company reported a net loss of $4.7 million for the half-year ended December 2025, though revenue from continuing operations grew 5% to $1.7 million.Kalkine MediaCan PainChek’s US Deal Redefine Aged Care Tech?PainChek has entered into an agreement with Sabra, enabling the large-scale deployment of its AI technology for assessing pain levels in aged care facilities. This agreement simplifies the adoption process and expands PainChek's global reach, facilitating faster integration by reducing financial and administrative barriers for facility operators.TipranksPainChek lifts UK aged care sales as global expansion gathers pacePainChek Ltd has secured 4,000 new contracted licences in the UK aged care market, representing 9% quarterly growth and expected to add approximately A$230,000 in annual recurring revenue once fully deployed. The company reports that its AI-powered pain assessment tool is gaining traction among UK providers, driven by clinically validated outcomes and operational efficiency benefits. PainChek is also advancing commercial initiatives in North America and developing an Infants product to expand its global footprint across additional markets and age groups.TipranksPainChek Options Lapse Simplifies Capital StructurePainChek Ltd announced the expiry of 6,354,951 unexercised options with an exercise price of $0.50 on 24 March 2026, as disclosed via an Appendix 3H notification. The lapse reduces the pool of potential dilutive securities and simplifies the company's capital structure, though it does not affect the number of ordinary shares currently on issue. This routine capital management event provides updated transparency on PainChek's outstanding securities profile without any immediate cash impact.